Last reviewed · How we verify
LY3185643
At a glance
| Generic name | LY3185643 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3185643 and rGlucagon in Healthy Participants (PHASE1)
- A Study of LY3143753 and LY3185643 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3185643 CI brief — competitive landscape report
- LY3185643 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI